<DOC>
	<DOCNO>NCT01098110</DOCNO>
	<brief_summary>A multicenter , randomize , parallel-group , double-blind , fix dose , 6-week trial efficacy safety asenapine compare placebo participant acute exacerbation schizophrenia .</brief_summary>
	<brief_title>6-week Trial Efficacy Safety Asenapine Compared Placebo Participants With Acute Exacerbation Schizophrenia ( P06124 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>current diagnosis schizophrenia paranoid , disorganize , catatonic , undifferentiated ( 295.90 ) subtype minimum Positive Negative Syndrome Scale ( PANSS ) total score 60 screen Baseline . participant score least 4 two 5 item positive subscale PANSS Screening Baseline . participant confirm investigator experience acute exacerbation schizophrenia evidence ALL following : screening test , duration current episode 2 month ; current symptom represent dramatic substantial change compare participant 's symptomatic state prior emergence current episode ; participant need change medication dosage treat newly appear worsened positive symptom . participant Clinical Global ImpressionsSeverity ( CGIS ) scale score least 4 ( moderately ill ) Baseline ; respond positively antipsychotic medication prior episode . discontinue use prohibit concomitant medication , last dose take later even prior baseline visit ( For depot neuroleptic , discontinuation must occur 3 month prior randomization ) . participant must agree inpatient status screen period 42 day dose , outpatient phase , caregiver identify responsible person ( e.g. , family member , social worker , case worker , nurse ) investigator accepts agree provide support participant ensure compliance study treatment , outpatient visit , protocol procedure . treatmentrefractory define follow criterion : ( 1 ) treat least two different atypical antipsychotic agent dosages equivalent great 600 mg/day chlorpromazine ( 12 mg /day haloperidol ) 4 week , without clinical response , ( 2 ) receive clozapine 12 week immediately precede screen . receive treatment 3 antipsychotic drug , doseequivalents higher 18 mg/day haloperidol ( equivalent 900 mg/day chlorpromazine ) within one month prior randomization . diagnosis schizoaffective disorder ; schizophrenia residual subtype ; schizophreniform disorder , schizophrenia course specifier continuous , single episode partial remission , single episode full remission concurrent psychiatric disorder schizophrenia cod Axis I ; primary diagnosis schizophrenia know diagnosis borderline personality disorder , mental retardation organic brain disorder . 20 % great decrease PANSS total score screen baseline imminent risk selfharm harm others , investigator 's opinion . substance induce psychotic disorder behavioral disturbance think due substance abuse currently involuntary inpatient confinement . previously treat asenapine .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>